February 20, 2020: Former passengers of the Diamond Princess cruise ship board a Taxi to leave after spending weeks on board in quarantine due to fears of spreading the COVID-19 Coronavirus in Yokohama. (Photo by Stanislav Kogiku/SOPA Images/LightRocket via Getty Images)
Princess Cruises, which had one of its ships quarantined off the coast of Japan last month, is suspending global operations through early May because of the coronavirus pandemic.
The cruise line, which is part of Carnival Corp., said Thursday that 18 cruise ships will cease voyages that were scheduled to depart between March 12 and May 10.
Japanese authorities quarantined the Diamond Princess cruise ship off the port of Yokohama for a two weeks after 10 passengers were initially diagnosed with the COVID-19.
The Miami cruise operator said those currently on cruises that will end in the next five days will continue to sail as expected so that travel arrangements aren't disrupted. Sailings underway that extend past March 17 will end at the most convenient location for guests, factoring in operational requirements.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
